Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Opioid-Related Disorders, Heroin Dependence, Morphine Dependence
Interventions: Transcranial Direct Current Stimulation (tDCS), Sham Transcranial Direct Current Stimulation (tDCS), Cognitive Training; Device · Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Device Ineffective, Device Induced Injury
Interventions: GentleFit Mask, GentleFit Prong, Standard of Care Interface; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 38 Weeks to 3 Years
Enrollment: 4 participants
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Subject
Interventions: Dietary Fiber, Fish Oil, Comparator; Dietary Supplement · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non-Surgical Fat Reduction
Interventions: CoolSculpting Elite System; Device
Lead sponsor: AbbVie; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Vista, California

Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Interventions: Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY; Combination Product · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 32
States / cities: Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more

Conditions: Intraoperative Ureter Visualization, Abdominolpelvic Surgery
Interventions: pudexacianinium chloride; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 12
States / cities: Los Angeles, California • Newport Beach, California • Tampa, Florida + 8 more

Conditions: Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities, Microdeletion Syndromes
Interventions: Not listed
Lead sponsor: Natera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,059 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2020
U.S. locations: 7
States / cities: San Carlos, California • San Gabriel, California • Washington D.C., District of Columbia + 4 more

Conditions: Urothelial Carcinoma Bladder
Interventions: Sasanlimab, Stereotactic Body Radiation Therapy, Radical Cystectomy + pelvic lymph node dissection + urinary diversion; Drug · Radiation · Procedure
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage
Interventions: Minimally Invasive surgery (MIS), Deferoxamine, Standard Medical Care (SMD); Procedure · Drug · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Thyroid Cancer
Interventions: Cerenkov luminescence imaging.; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions: 3-Dimensional Conformal Radiation Therapy, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Veliparib; Radiation · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2026
U.S. locations: 232
States / cities: Anchorage, Alaska • Tucson, Arizona • Beverly Hills, California + 158 more

Conditions: Unwanted Fat
Interventions: UltraShape Contour I V3; Device
Lead sponsor: Syneron Medical; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Boca Raton, Florida • Great Neck, New York • New York, New York

Conditions: Pancreatic Cyst, Pancreatic Mucinous Cystic Neoplasm
Interventions: Tamoxifen 20mg; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Interventions: Closed-loop tACS, Sham Comparator; Device
Lead sponsor: Pulvinar Neuro, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Post Operative Ileus
Interventions: Not listed
Lead sponsor: VA Greater Los Angeles Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: HER2/Neu Positive, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Entinostat, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Trastuzumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography; Procedure · Other · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 5
States / cities: Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more

Conditions: Study is Open to Seniors Age 50 or Older
Interventions: Pharmacist Pneumococcal Vaccine Program (PPVP); Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 50 Years and older
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Parkinson Disease
Interventions: Active vibrotactile coordinated reset, Sham vibrotactile coordinated reset; Device
Lead sponsor: Synergic Medical Technologies, Inc.; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Neer Infrared Spectroscopy; Device
Lead sponsor: Keck School of Medicine of USC; Other
Eligibility: 1 Hour to 24 Hours
Enrollment: 50 participants
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fibrosis Lung
Interventions: FAPI tracer, PET/MRI; Drug · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lymphoma, Infection, Leukemia
Interventions: Fluconazole, Voriconazole; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Stanford, California + 25 more

Conditions: Tinnitus Aggravated, Tinnitus, Tinnitus, Subjective
Interventions: neurofeedback-guided brain connectivity modulation, sham neurofeedback-guided brain connectivity modulation; Behavioral
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Individuality
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 64 Years
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Opioid Use Disorder

GentleFit Non-Invasive Ventilation (NIV) Interface Trial

Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer

A Study to Assess Non-Invasive Subcutaneous Fat Reduction in the Submental, Inner Thigh and Back/Bra Areas With the CoolSculpting Elite System

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

A Study to Find Out if ASP5354 Can Clearly Help Show the Ureter During Surgery in People With or Without Kidney Disease

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer

Synergistic Minimally Invasive Surgery and Deferoxamine in ICH

A Study of Optical Imaging With Light From Radiotracers in Cancer Patients

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Non-Invasive Abdominal Fat Reduction With BMI Above 28

Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection

Individualized Non-invasive Brain Stimulation for the Treatment of Major Depressive Disorder

Predictive Validity of Acoustic Gastrointestinal Surveillance (AGIS) in Post-Operative Feeding

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center

Vibrotactile Coordinated Reset: A Non-invasive Treatment for Parkinson's Disease 2

Application of Lung Near-Infrared Spectroscopy (NIRS) in Preterm Infants

Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)

Non-Invasive Neurofeedback Training to Alleviate Tinnitus Distress

Non-Invasive Brain-Computer Interface for Virtual Object Control